Medical note: This is general education, not personal medical advice. ED can be related to cardiovascular disease, diabetes, medication effects, mental health, neurologic disease and other conditions. Persistent or new ED deserves appropriate medical evaluation.
In This Article
- Eroxon is a drug-free topical gel that the FDA authorized through the De Novo pathway in June 2023 as a Class II medical device for treating ED in men 22 and older, with no prescription needed.
- It works by a rapid cooling-then-warming effect on the head of the penis that stimulates nerve endings, not by changing blood chemistry like a pill.
- In the study FDA reviewed, 62% of men met the threshold for meaningful improvement and 62.6% noticed an erection within 10 minutes.
- As of October 2026, Eroxon's U.S. distribution has moved from Haleon to Market Performance Group; check current retailer listings before buying.
For decades, every effective ED treatment in the U.S. needed a prescription. Eroxon changed that. It's a gel you rub on the head of the penis shortly before sex, it contains no drug, and the FDA authorized it for sale without a prescription. That combination makes it one of the most talked-about ED products of the last few years, and one of the most misunderstood.
Here's what Eroxon actually is, how its regulatory status differs from a pill, what the study data showed, and who it may suit.
What Eroxon is
Eroxon (developed by Futura Medical as MED3000) is a hydro-alcoholic gel supplied in single-use tubes. The ingredients listed in the U.S. brand's healthcare-professional FAQ are alcohol, water, glycerin, propylene glycol, carbomer and potassium hydroxide, none of which is an active pharmaceutical ingredient.
The FDA's review describes how it works: the gel's volatile components evaporate after it's applied to the glans (head of the penis), producing a rapid cooling effect followed by slower warming. That temperature change stimulates nerve endings and blood flow, leading to an erection. It's a physical effect, which is why Eroxon is regulated as a medical device rather than a drug.
Its regulatory status, precisely
| Item | Status (verified October 2026) |
|---|---|
| FDA pathway | De Novo classification request (DEN220078), submitted by Futura Medical Developments in October 2022 |
| Authorization date | June 9, 2023, the date FDA issued the classification order |
| Device class | Class II (special controls), under the new device type "non-medicated topical formulation for treatment of erectile dysfunction," 21 CFR 876.5021. FDA published the formal classification rule in July 2026 |
| Indication | Treatment of erectile dysfunction in adult males aged 22 years and over |
| Prescription needed? | No. Marketed over the counter |
| U.S. commercial partner | Haleon launched it in September 2024 (Amazon preorders, then major retailers). Futura ended the Haleon agreement in 2026; Market Performance Group took over U.S. distribution on September 1, 2026 |
Two wording points matter. First, Eroxon was authorized as a device, not "approved" as a drug in the way Viagra or Cialis were. Haleon's launch materials called it "FDA cleared." Second, its OTC status reflects the device route: there's no medication in it to interact with your other drugs in the usual way.
Futura's announcements in 2026 also described a stronger version, Eroxon Intense, which has EU clearance and was expected to receive a U.S. FDA decision in late 2026. As of this writing, that U.S. decision isn't something we could confirm. Futura also warned in September 2026 that its cash would fund operations only until about October without additional funding, so U.S. availability could change. Check retailer listings before you plan around it.
What the evidence shows
The FDA's De Novo review summarizes the pivotal U.S. study. It was a 24-week, multi-center, randomized, open-label, home-use trial. 48 men used Eroxon and 48 took tadalafil 5 mg, but the tadalafil group was exploratory only. The study wasn't designed to compare the two, so it doesn't tell you which works better.
- Erectile function score: mean improvement of 5.73 points on the IIEF erectile function domain at 24 weeks.
- Responders: 62% of Eroxon users improved by more than 4 points, a commonly used threshold for a meaningful change.
- Speed: 62.6% noticed an erection within 10 minutes, and 55.7% were able to have penetrative sex within 15 minutes.
- Side effects: one Eroxon user (2.1%) had a treatment-related burning sensation at the application site. Three of six Eroxon withdrawals were due to lack of effect.
Keep the limits in mind. The study was small and open-label (men knew what they were using), and it excluded men taking nitrates or alpha-blockers. Haleon's marketing says it "helps you get an erection within 10 minutes," with individual results varying.
How it's used
According to the U.S. brand's materials, you use one full tube per attempt, massaging it onto the head of the penis (pulling back the foreskin first if uncircumcised) for about 15 seconds. A partner can apply it as part of foreplay. Sexual stimulation is still required. The brand notes that some men need a few attempts, and some practice alone first.
Who shouldn't use it
- Are under 22
- Are allergic to any ingredient
- Have a disease or deformity of the penis, such as Peyronie's disease
- Have red, sore, damaged or broken skin on the penis
- Have been advised by a doctor to avoid sexual activity
Stop if it causes burning, itching or redness, and get medical advice if irritation continues.
Condoms and contraception: Eroxon is not a contraceptive. FDA requires the labeling to include condom compatibility information. The FDA review lists latex, polyisoprene and polyurethane condoms as compatible based on bench testing, while the U.S. brand's healthcare-professional FAQ says it isn't compatible with polyurethane condoms. Check the current package insert for your condom type.
Other ED treatments: the brand says use alongside PDE5 inhibitors hasn't been studied. Don't combine treatments without asking a clinician.
Heart health: Eroxon contains no drug, but sex itself carries some cardiac risk. If you've been told to avoid sexual activity, the label says not to use it, and ED itself can be an early sign of heart disease worth checking. See our article on why new ED warrants a heart conversation.
Eroxon vs. ED pills
| Eroxon gel | PDE5 pills (sildenafil, tadalafil) | |
|---|---|---|
| Prescription | No | Yes, in the U.S. |
| What it is | Drug-free gel; medical device | Drug that blocks the PDE5 enzyme |
| How fast | Erection within 10 minutes for 62.6% in the pivotal study | Sildenafil label: take about 1 hour before sex; tadalafil lasts longer |
| Nitrate contraindication | Not listed for the gel itself; men on nitrates were excluded from the study | Absolute contraindication |
| Common side effects | Application-site burning or itching | Headache, flushing, congestion, indigestion |
| Evidence base | Smaller, newer | Decades of trials and real-world use |
Eroxon may appeal to men who want to try something without a prescription, who can't take PDE5 inhibitors, or who want speed and spontaneity. Men with more severe or vascular ED may find pills or other treatments more reliable. Our guide to buying ED medication over the counter explains why PDE5 pills remain prescription-only in the U.S., and our topicals pipeline report covers what else is in development.
Sources
- FDA: De Novo decision summary for Eroxon (DEN220078)
- Federal Register (July 2026): Classification of the non-medicated topical formulation for treatment of erectile dysfunction
- Haleon (September 2024): Eroxon U.S. launch announcement
- Futura Medical (June 2026): New US commercial partner
- Haleon: Eroxon Product FAQs for Healthcare Professionals